Biocon Biologics to get Rs 225 cr from Tata Capital Growth Fund for 0.85 per cent equity stake
Post the completion of this transaction, Biocon will hold 95.25 per cent stake in Biocon Biologics
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biosimilars
Biocon Biologics receives EU GMP Certification for multiple Biosimilars manufacturing facilities in…
These facilities are used for the manufacture of DS and DP for Biosimilars: Bevacizumab, Trastuzumab, Pegfilgrastim and secondary…
FDA and FTC announce new efforts to further deter anti-competitive business practices, support…
The joint statement describes key steps the agencies will take to address false or misleading promotion about biosimilars within…
Lupin sells stakes in Kyowa but its not a Sayonara
With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…
The new realities in pharma R&D
It is pivotal for India’s pharma R&D playbook to evolve and become more agile and responsive with the help of technology and…
CPhI India Report identifies two-tier manufacturing market and predicts increased acquisitions
CDSCO certification has improved international repute of India, but domestic companies call for urgent Government support to…
TAKE Solutions acquires Ecron Acunova
Targets the largely untapped biosimilars, regenerative medicine and diagnostic imaging agents space by increasing its IP assets
Biocon-Mylan programmes make clinical progress
PEG-G-CSF and Adalimumab enter phase II while patient recruitment for one insulin Glargine phase II study is complete Biocon has…